KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Free Cash Flow (2018 - 2025)

Castle Biosciences' Free Cash Flow history spans 7 years, with the latest figure at $20.0 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 22.73% year-over-year to $20.0 million; the TTM value through Dec 2025 reached $53.0 million, down 18.28%, while the annual FY2025 figure was $53.0 million, 18.28% down from the prior year.
  • Free Cash Flow for Q4 2025 was $20.0 million at Castle Biosciences, down from $25.0 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $36.1 million in Q3 2024 and bottomed at -$28.8 million in Q1 2023.
  • The 5-year median for Free Cash Flow is -$5.3 million (2021), against an average of $1.4 million.
  • The largest annual shift saw Free Cash Flow tumbled 457.31% in 2022 before it soared 352.48% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at -$6.1 million in 2021, then crashed by 72.88% to -$10.5 million in 2022, then soared by 155.88% to $5.9 million in 2023, then soared by 341.97% to $25.9 million in 2024, then dropped by 22.73% to $20.0 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Free Cash Flow are $20.0 million (Q4 2025), $25.0 million (Q3 2025), and $17.2 million (Q2 2025).